Literature DB >> 20092080

What's new in trial design: propensity scores, equivalence, and non-inferiority.

Paul S Myles1.   

Abstract

Recent modifications to traditional clinical research designs include propensity scores, equivalence, and non-inferiority trials, as well as greater use of pooled endpoints for primary outcome measures. Each of these innovations offers benefits, but they have been misused. Propensity score techniques can account for imbalance in treatment group allocation to provide more accurate estimates of benefit or risk. Unlike clinical trials, they typically represent real world, everyday practice and so their findings may in fact be less biased. Equivalence and non-inferiority designs can tailor clinical trials to address clinically meaningful questions: Is a proposed new technique at least as good as current treatment? Pooled endpoints can summarize a range of beneficial outcomes as well as reduce the required sample size. A clearer understanding of bias and confounding, and the interpretation of the 95% confidence interval of the estimated treatment effect are central to proper use of these techniques.

Mesh:

Year:  2009        PMID: 20092080      PMCID: PMC4813540     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  32 in total

1.  Claims of equivalence in medical research: are they supported by the evidence?

Authors:  W L Greene; J Concato; A R Feinstein
Journal:  Ann Intern Med       Date:  2000-05-02       Impact factor: 25.391

Review 2.  Validity of composite end points in clinical trials.

Authors:  Victor M Montori; Gaietà Permanyer-Miralda; Ignacio Ferreira-González; Jason W Busse; Valeria Pacheco-Huergo; Dianne Bryant; Jordi Alonso; Elie A Akl; Antònia Domingo-Salvany; Edward Mills; Ping Wu; Holger J Schünemann; Roman Jaeschke; Gordon H Guyatt
Journal:  BMJ       Date:  2005-03-12

3.  Trials and tribulations of non-inferiority: the ximelagatran experience.

Authors:  Sanjay Kaul; George A Diamond; William S Weintraub
Journal:  J Am Coll Cardiol       Date:  2005-11-09       Impact factor: 24.094

Review 4.  Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement.

Authors:  Peter C Austin
Journal:  J Thorac Cardiovasc Surg       Date:  2007-11       Impact factor: 5.209

5.  Lessons from and cautions about noninferiority and equivalence randomized trials.

Authors:  Peter C Gøtzsche
Journal:  JAMA       Date:  2006-03-08       Impact factor: 56.272

6.  Platelet transfusion in cardiac surgery does not confer increased risk for adverse morbid outcomes.

Authors:  Tory McGrath; Colleen Gorman Koch; Meng Xu; Liang Li; Tomislav Mihaljevic; Priscilla Figueroa; Eugene H Blackstone
Journal:  Ann Thorac Surg       Date:  2008-08       Impact factor: 4.330

Review 7.  Clinical trials: how to assess confounding and why so.

Authors:  Ton J Cleophas; Aeilko H Zwinderman
Journal:  Curr Clin Pharmacol       Date:  2007-05

Review 8.  Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials.

Authors:  R Collins; S MacMahon
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

Review 9.  From randomized controlled trials to observational studies.

Authors:  Stuart L Silverman
Journal:  Am J Med       Date:  2009-02       Impact factor: 4.965

10.  A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.

Authors:  Keyvan Karkouti; W Scott Beattie; Kathleen M Dattilo; Stuart A McCluskey; Mohammed Ghannam; Ahmed Hamdy; Duminda N Wijeysundera; Ludwik Fedorko; Terrence M Yau
Journal:  Transfusion       Date:  2006-03       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.